NCT03018080View on ClinicalTrials.gov

Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

July 29, 2021

Study Completion Date

August 5, 2022

Conditions
Breast - FemaleMale Breast Cancer
Interventions
DRUG

Pembrolizumab

IV (in the vein) on day 1 of a 21 day cycle

DRUG

Paclitaxel

IV (in the vein) on days 1 and 8 of a 21 day cycle

Trial Locations (1)

28204

Levine Cancer Institute, Charlotte

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER

NCT03018080 - Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer | Biotech Hunter | Biotech Hunter